Vorasidenib
Vorasidenib is an experimental anti-cancer medication for the treatment of low-grade glioma. It is a small molecule inhibitor of isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2), which are mutated in several forms of cancer.[1] In a phase-III-trial, it was shown to prolong progression-free survival in patients with IDH1- or IDH2-mutant low-grade glioma.[2]
![]() | |
Clinical data | |
---|---|
License data |
|
Drug class | Antineoplastic agent |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C14H13ClF6N6 |
Molar mass | 414.74 g·mol−1 |
3D model (JSmol) | |
| |
|
See also
References
- "Vorasidenib compound summary". pubchem. 2 September 2023. Retrieved 6 September 2023.
- Mellinghoff, Ingo K.; et al. (2023-08-17), "Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma", New England Journal of Medicine, vol. 389, no. 7, pp. 389–601, doi:10.1056/NEJMoa2304194, PMC 5900343, PMID 29670690
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.